What olpasiran is
Olpasiran is a small interfering RNA (siRNA), a short double-stranded RNA molecule that harnesses the cell's natural RNA-interference machinery to destroy a specific messenger RNA. Olpasiran targets the RNA from the LPA gene, which carries instructions for making apolipoprotein(a), the protein that defines lipoprotein(a), or Lp(a). With less apolipoprotein(a), the liver releases far less Lp(a) into the blood. Olpasiran is developed by Amgen and is given as an injection under the skin every 12 weeks or less often.
Why Lp(a) matters
Lp(a) levels are largely inherited and barely respond to diet or exercise. Genetic studies, including a 2009 analysis in the New England Journal of Medicine, found that variants raising Lp(a) are associated with markedly higher risk of coronary disease. That genetic evidence is the main reason several companies are developing Lp(a)-lowering drugs. See What Is Genomics?
Clinical evidence
Phase 2: OCEAN(a)-DOSE
OCEAN(a)-DOSE enrolled 281 patients with established cardiovascular disease and a median Lp(a) of 260.3 nmol/L, most already taking statins. At 36 weeks, the placebo-adjusted mean changes in Lp(a) were:
| Dose | Placebo-adjusted change in Lp(a) |
|---|---|
| 10 mg every 12 weeks | −70.5% |
| 75 mg every 12 weeks | −97.4% |
| 225 mg every 12 weeks | −101.1% |
| 225 mg every 24 weeks | −100.5% |
Source: O'Donoghue et al., NEJM (2022). Reductions slightly above 100% reflect placebo adjustment, since Lp(a) rose by a mean of 3.6% in the placebo group.
Durability
In the extension period, reported in the Journal of the American College of Cardiology in 2024, Lp(a) stayed substantially lower after dosing stopped. Patients who had received 75 mg or more every 12 weeks had roughly 40% to 50% lower Lp(a) close to a year after their last dose. No new safety concerns were identified during the off-treatment follow-up.
Phase 3: outcomes trials
| Trial | Population | Primary endpoint | Size | Status (registry) |
|---|---|---|---|---|
| OCEAN(a)-Outcomes | Established atherosclerotic cardiovascular disease and elevated Lp(a) | Time to coronary heart disease death, heart attack, or urgent coronary revascularization | 7,297 | Active, not recruiting; estimated primary completion March 2028 |
| OCEAN(a)-PreEvent | People without a prior major cardiovascular event (primary prevention) | Same coronary composite | Estimated 11,000 | Recruiting |
Scientific perspective
Olpasiran has demonstrated what it was designed to do: near-complete, durable suppression of Lp(a). What it has not yet shown is that this prevents heart attacks. That is a question only an outcomes trial can answer.
In September 2026 the answer became much less certain. Pelacarsen, an antisense drug that lowered Lp(a) by about 78%, did not reduce major cardiovascular events in the 8,323-patient Lp(a)HORIZON trial. See the pelacarsen profile. There are real differences between the drugs and trials, any of which could matter:
- Depth of lowering. Olpasiran's Phase 2 reductions exceeded 95% at the doses being tested, compared with about 78% for pelacarsen in its outcomes trial.
- Endpoint. OCEAN(a)-Outcomes uses a coronary composite: coronary death, heart attack, or urgent coronary revascularization.
- Population and duration. Trial populations, background therapy, and follow-up times differ.
None of these differences guarantees a different result. The pelacarsen outcome shows that strong genetic evidence for a risk factor does not by itself guarantee that lowering it with a drug will prevent events. This is a central caution in What Is a Primary Clinical Trial Endpoint?
Development perspective
- Regulatory status: olpasiran has no FDA approval and, to our knowledge, has not been submitted for approval. Approval for cardiovascular risk reduction would be expected to depend on a positive outcomes trial.
- Key catalyst: the OCEAN(a)-Outcomes readout. The registry estimates primary completion in March 2028. Sponsors' estimated dates often move, and changes will be logged on this page.
- Historical benchmark: for an average Phase 3 program, 57.8% have historically advanced to an application and about 52% to approval. This benchmark predates the pelacarsen result and does not account for it. It describes programs in general, not this drug.
Competitive context
Lp(a) is now one of the most closely watched targets in cardiovascular drug development, with antisense (pelacarsen), siRNA (lepodisiran, zerlasiran), and oral (muvalaplin) approaches all in clinical testing. After Lp(a)HORIZON, investors and clinicians are likely to treat each remaining outcomes trial as a test of the Lp(a) hypothesis itself, not only of the individual drug.
Development timeline
- Jul 28, 2020OCEAN(a)-DOSE Phase 2 dose-finding trial begins. Registry
- Nov 6, 2022OCEAN(a)-DOSE results published: placebo-adjusted Lp(a) reductions of up to about 101% at 36 weeks. Peer-reviewed
- Dec 14, 2022OCEAN(a)-Outcomes Phase 3 cardiovascular outcomes trial begins. Registry
- Aug 27, 2024Extension results published: Lp(a) remained about 40% to 50% lower close to a year after the last dose at 75 mg or more. Peer-reviewed
- Aug 22, 2025OCEAN(a)-PreEvent, a primary-prevention outcomes trial with an estimated 11,000 participants, begins. Registry
- Sep 4, 2026Read-across: pelacarsen, a different Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported
What could change the outlook
- The OCEAN(a)-Outcomes result, the decisive test of whether olpasiran reduces coronary events. The registry lists estimated primary completion in March 2028.
- Whether the deeper Lp(a) lowering achieved by olpasiran, compared with pelacarsen, translates into a different clinical outcome.
- Any changes to OCEAN(a)-Outcomes or OCEAN(a)-PreEvent in the registry, such as endpoint, size, or timing amendments, following the pelacarsen result.
- Long-term safety data, given the drug's prolonged effect after dosing.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Olpasiran. Company-reported, not independently verified.
- Quarterly reportCompany-reportedNov 3, 2026
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
Olpasiran (AMG 890) • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV...
- Quarterly reportCompany-reportedAug 4, 2026
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Olpasiran (AMG 890) • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV...